Budget impact of Rinzimetostat
4 evidence topics · 21 sources
Summary: price status of rinzimetostat and darolutamide
- Rinzimetostat is investigational. ORIC states that it has “not submitted for, or obtained, regulatory approval for any product candidate” and has “no products approved for commercial sale”. The Himalayas-1 phase 3 trial (NCT07723248) of rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily is recruiting, with an actual start date of 3 August 2026 and an estimated primary completion date of March 2028.
- No wholesale acquisition cost, average sales price, brand name, or unit strength of rinzimetostat was identified. ORIC describes post-abiraterone mCRPC as “a $3.5bn total addressable market annually in the US”, and its presentation notes that the figure “assumes current price of ARPIs for illustrative purposes”.
- Darolutamide (Nubeqa, Bayer) is supplied as 300 mg tablets in bottles of 120 tablets. A filing with the California Department of Health Care Access and Information reports a wholesale acquisition cost of $15,100.80 for the 120-tablet bottle (NDC 50419039501), effective 1 January 2026, after an increase of $847.20.
- The labeled darolutamide dose is 600 mg orally twice daily with food, with a concurrent GnRH agonist or antagonist or prior bilateral orchiectomy; for grade 3 or higher or intolerable adverse reactions the dose is withheld or reduced to 300 mg twice daily. Its labeled indications are nmCRPC and mCSPC (alone or in combination with docetaxel); mCRPC is not a labeled indication.
- For Himalayas-1, Bayer provides darolutamide “at no cost for use in the trial in combination with rinzimetostat”, and ORIC retains global development and commercial rights to rinzimetostat.
Summary: comparator prices and costs of care
- The physician's choice control arm of Himalayas-1 comprises darolutamide 600 mg twice daily, enzalutamide 160 mg once daily, or docetaxel 75 mg/m2 intravenously every 21 days for up to 10 cycles.
- Enzalutamide (Xtandi): the Medicare negotiated price effective 1 January 2027 is $7,004 per 30-day supply, 48% below the calendar year 2024 list price (wholesale acquisition cost) of $13,480.
- Medicare Part B payment limits for 1 October to 31 December 2026, based on second-quarter 2026 ASP data: docetaxel $0.471 per mg; cabazitaxel $231.688 per mg; sipuleucel-T $55,663.131 per infusion; pembrolizumab $62.253 per mg; denosumab $29.856 per mg; zoledronic acid $17.673 per mg. The file lists no payment limit for radium-223 dichloride (“N/A”) and notes $212.84 per microCurie at 100% of AWP and $177.37 per microCurie at 100% of WAC.
- Hospital outpatient payment rates for October 2026 are $180.422 for radium-223 dichloride (A9606, APC 1745) and $266.541 for lutetium Lu 177 vipivotide tetraxetan (A9607, APC 9054).
- Lutetium Lu 177 vipivotide tetraxetan has no ASP-based benchmark. Authors employed by Sanofi, the manufacturer of cabazitaxel, estimated a per-dose cost of $55,522 from the median Medicare Administrative Contractor payment rate, assuming a 200-mCi dose. A published U.S. model used per-cycle costs of $32,062 for lutetium Lu 177 vipivotide tetraxetan, based on the price of 177Lu-DOTATATE as a proxy, and $14,382 for cabazitaxel.
- Costs of care in a cohort of 14,780 men with mCRPC (2019 USD): mean all-cause medical and pharmacy costs per patient per year were $27,468 in the year before mCRPC diagnosis, $148,325 during first-line, $160,118 during second-line, and $165,186 during third-line therapy. In 296 patients progressing from mCSPC to mCRPC, mean all-cause total costs per patient per month increased from $4,424 to $9,717.
Summary: eligible population inputs
- ORIC estimates that “the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000” in the U.S., and states that abiraterone has maintained “>50% market share of new prescriptions over the last five years”. These are company-reported figures. No peer-reviewed estimate of the U.S. annual number of men with mCRPC previously treated with abiraterone was identified.
- A U.S. model estimated mCRPC incidence of 36,100 in 2009 and 42,970 in 2020, with 86% of incident mCRPC arising from the nmCRPC clinical state.
- In a real-world cohort of 5,361 patients, 867 (16.2%) had received an ARPI alone and 83 (1.5%) an ARPI and a taxane before mCRPC diagnosis; ARPI-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023, and 76.8% of patients received an ARPI as first-line mCRPC treatment.
- Among 14,780 men newly diagnosed with mCRPC in Medicare fee-for-service claims (January 2014 to June 2019), 78% received at least one line of therapy, 42% at least two, and 20% at least three. Abiraterone accounted for 36% of first-line, 28% of second-line, and 17% of third-line therapy; enzalutamide for 28%, 33%, and 19%; and docetaxel for 16%, 15%, and 24%.
Summary: published comparator models
- No budget impact model or cost-effectiveness analysis of rinzimetostat was identified.
- A U.S. payer budget impact model of darolutamide in nmCRPC for a hypothetical 1-million-member plan over 5 years estimated approximately 90 incident nmCRPC cases each year and 332 treatment-eligible cases by year 5; introducing darolutamide along with other targeted therapies increased the budget by $158,640 ($0.0132 PMPM) in year 1 and saved $149,240 ($0.0124 PMPM) by year 5.
- A U.S. budget impact analysis of hospitalization costs with darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer, over a 5-year horizon, reported a cumulative budget impact of -$9.71 per treated member per month.
- A U.S. health care partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel (60-month horizon) estimated an incremental cost of $36,258, an incremental gain of 0.10 QALYs, and an ICER of $358,990 per QALY gained. Authors employed by Sanofi state that the model used the price of 177Lu-DOTATATE as a proxy and that “the magnitude of difference is likely greater than reported”.
- A U.S. payer model of third-line cabazitaxel versus a second androgen receptor-targeted agent (18-month horizon) estimated $323,095 (17%) in avoided total costs, 58 fewer hospitalization days, and 2 fewer ICU days.
- A U.S. payer model of genomic test-directed olaparib after a new hormonal agent estimated an ICER of $116,903 per QALY in one scenario and cost savings of $1,980 in the other.